on OXURION (EBR:OXUR)
Oxurion 2025 Half-Year Results: Financial and Operational Analysis
On September 30, 2025, biopharmaceutical company Oxurion NV, listed on Euronext Brussels under the ticker OXUR, published its financial results for the first half of the year. This report covers the period ending June 30, 2025, and is available online in the investor section of the website. Leuven-based Oxurion focuses on majority stakes in European pharmaceutical contract manufacturers. The company aims to create an integrated group to support the healthcare sector.
It is important to note that this press release includes forward-looking statements that are subject to risks and uncertainties. The company undertakes no obligation to update these statements. Finally, Oxurion cautions against investing in digital assets, such as Bitcoin and Ethereum, due to their volatility and uncertain regulatory environment, which could affect investment performance.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all OXURION news